← Leaderboards
Andrew John Buckler
Elucid
$4,568,969
Attributed
$4,568,969
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1M · FY2015–21$2M$1.5M$1M$500K$0
'15
'16
'17
'18
'19
'20
'21
Funding mix
By agency
NIH$4,568,969 · 1
By mechanism
R44$4,568,969 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Novel Therapeutics”
- David Heimbrook · Leidos Biomedical Research, Inc.$355,066,875
- Judith S. Currier · University Of California Los Angeles$321,442,024
- Gerald T Nepom · Benaroya Research Inst At Virginia Mason$298,740,071
- Leonard Freedman · Leidos Biomedical Research, Inc.$263,124,404
- Daniel R Kuritzkes · Brigham And Women'S Hospital$246,024,897
- Sharon A Nachman · Johns Hopkins University$212,395,175
Research focus
Novel TherapeuticsModalityDecision MakingImage AnalysisLipidsMeasurementCoronary ArteriosclerosisData SetImageHistologyCollectionLesionBaseManualsBioimagingComputer AssistedArterial Fatty StreakCardiovascular DiseasesDetectionCharacteristicsDiagnosisEventAtherosclerosisPerformance
Grant awards (5)
Plaque Risk Stratification Using Routinely Available CCTA to Optimize Therapeutic Decision-making in Patients with Known or Suspected Coronary Artery Disease$984,177
R44 · FY2021 · HL · contact PI
Plaque Risk Stratification Using Routinely Available CCTA to Optimize Therapeutic Decision-making in Patients with Known or Suspected Coronary Artery Disease$1,011,405
R44 · FY2020 · HL · contact PI
Plaque Risk Stratification Using Routinely Available CCTA to Optimize Therapeutic Decision-making in Patients with Known or Suspected Coronary Artery Disease$991,516
R44 · FY2019 · HL · contact PI
vascuCAP: Non-invasive Computer-Aided Phenotyping of Vasculopathy$783,030
R44 · FY2016 · HL · contact PI
vascuCAP: Non-invasive Computer-Aided Phenotyping of Vasculopathy$798,841
R44 · FY2015 · HL · contact PI